DUBLIN – Shares in Saniona AB gained 25 percent Monday on news of an ion channel drug discovery pact in schizophrenia with Boehringer Ingelheim GmbH worth up to €90 million (US$101 million) in up-front and milestone payments. Read More
Amgen Inc., of Thousand Oaks, Calif., said that new analyses of data show Repatha (evolocumab) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients across cardiovascular risk subgroups or with familial hypercholesterolemia. Read More
NLS Pharma Group, of Stans, Switzerland, started enrollment for a phase II experiment to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release formulation of mazindol in adults with DSM-5 attention deficit hyperactivity disorder (ADHD). Read More
With a potential generic already in the wings, Eli Lilly and Co. is hoping to bring the curtain down permanently on ANDAs referencing its blockbuster osteoporosis drug Forteo. Read More
Top-line data from CTI Biopharma Corp.'s phase III trial of pacritinib, a JAK2/FLT3 multikinase inhibitor for high-risk patients with advanced myelofibrosis showed the treatment demonstrated statistically significant improvement in spleen volume reduction vs. best available treatment. Read More
Mylan NV's announcement Monday that it will launch a generic of its Epipen did little to quell the public shaming as skeptics speculated about the motives behind the move. Read More
Five-year-old Leap Therapeutics Inc. stands to become a public company as the surviving entity in its merger with the Israeli biopharma, Macrocure Ltd., which will operate as a wholly owned subsidiary. Leap, of Cambridge, Mass., was founded in 2011 and raised $30.5 million the same year in a round led by Healthcare Ventures and its funds, according to SEC filings. Earlier this year, Healthcare Ventures was said to have combined its portfolio companies Healthcare Pharmaceuticals Inc. and GITR Inc. into Leap. Read More
TOKYO – Takeda Pharmaceutical Co. Ltd., of Japan, plans to restructure its research and development operations to focus primarily on the areas of oncology, gastroenterology and central nervous system, as well as vaccines. Read More
SHANGHAI – Newly created oncology biotech, CBT Pharmaceuticals, of Santa Clara, Calif., has received $9.75 million in series A financing from venture investors led by Orbimed Healthcare Fund Management Asia, with an additional $2 million available in warrants. Read More
